20 patents
Utility
Androgen Receptor Modulators and Methods for Their Use
23 Nov 23
The present invention relates to compounds of formula (ABC), (BC), (A), (B), (B-I), (C), (C-I), (D), (D-I), (E), (E-I), (F), (G), (H), (J), or (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie ZHOU, Peter VIRSIK, Berenger BIANNIC
Filed: 24 Apr 23
Utility
Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
14 Nov 23
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 5 Dec 22
Utility
Solid Forms of an N-terminal Domain Androgen Receptor Inhibitor and Uses Thereof
6 Apr 23
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie ZHOU, Peter VIRSIK
Filed: 5 Dec 22
Utility
Androgen Receptor Modulators and Methods for Use As Proteolysis Targeting Chimera Ligands
16 Mar 23
The present invention relates to bifunctional Proteolysis Targeting Chimeric ligands (Protac compounds) comprising a ligase modulator/binder and a molecule that binds to a protein target of interest, and methods of treating various diseases and conditions with the Protac compounds, including diseases associated with androgen receptors.
Han-Jie Zhou, Raymond John Andersen
Filed: 27 Mar 20
Utility
Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
6 Dec 22
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 28 Apr 22
Utility
Androgen Receptor Modulators and Methods for Their Use
1 Dec 22
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
Filed: 30 Jun 21
Utility
Androgen Receptor Modulators and Methods for Their Use
1 Dec 22
The present invention relates to compounds of formula (A), (A-I), (A-II), (A-III), (B), (B-I), (C), (D), (E), (E-I), (F), (G), (H), (J), and (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie ZHOU, Peter Virsik, Berenger Biannic
Filed: 22 Apr 22
Utility
Androgen receptor modulators and methods for their use
1 Nov 22
Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided.
Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
Filed: 24 May 19
Utility
Solid Forms of an N-terminal Domain Androgen Receptor Inhibitor and Uses Thereof
18 Aug 22
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 28 Apr 22
Utility
Pharmaceutical Compositions and Combinations Comprising Inhibitors of the Androgen Receptor and Uses Thereof
14 Jul 22
The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen.
Peter Virsik, Han-Jie Zhou, Marianne Dorothy Sadar, Raymond John Andersen, Kunzhong Jain, Daniel Andrew Golec
Filed: 27 Mar 20
Utility
Pharmaceutical Compositions and Combinations Comprising Inhibitors of the Androgen Receptor and Uses Thereof
30 Jun 22
The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor modulator or an inhibitor and a second therapeutically active agent, such as an antiandrogen.
Peter Virsik, Han-Jie Zhou, Ronan Le Moigne
Filed: 27 Mar 20
Utility
Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
14 Jun 22
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 15 Nov 21
Utility
Solid Forms of an N-terminal Domain Androgen Receptor Inhibitor and Uses Thereof
10 Mar 22
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 15 Nov 21
Utility
Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
8 Feb 22
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 9 Jun 21
Utility
Solid Forms of an N-terminal Domain Androgen Receptor Inhibitor and Uses Thereof
28 Oct 21
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 9 Jun 21
Utility
Solid Forms of an N-terminal Domain Androgen Receptor Inhibitor and Uses Thereof
21 Oct 21
The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof.
Han-Jie Zhou, Peter Virsik
Filed: 16 Apr 21
Utility
Androgen receptor modulators and methods for their use
13 Jul 21
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
Filed: 20 Apr 20
Utility
Androgen Receptor Modulators and Methods for Their Use
1 Jul 21
Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided.
Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
Filed: 24 May 19
Utility
Androgen Receptor Modulators and Methods for Their Use
5 Aug 20
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie Zhou, Peter Virsik
Filed: 19 Apr 20
Utility
Androgen Receptor Modulators and Methods for Their Use
22 Apr 20
The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer.
Han-Jie Zhou, Peter Virsik
Filed: 17 Oct 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first